Tumor microenvironment-activated Zn//MnO<sub>2</sub> battery for sustained and local electrochemical immunotherapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 40435257.
- Also identified by DOI 10.1126/sciadv.adu1647 and PMC identifier 12118630.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Metal ions are widely adopted to potentiate oxidative damage-induced immunogenic cell death (ICD) and regulate immune pathways. However, current ion delivery platforms lack precise administration over distribution and retention time within the tumor microenvironment, leading to high systemic toxicity and suboptimal therapeutic efficacy. Here, local electrochemical immunotherapy is developed by implanting a tumor microenvironment-activated Zn//MnO<sub>2</sub> battery, which uses body fluid as an electrolyte and endogenous glutathione as a redox mediator to promote sustained generation and localized retention of electrochemical products (Zn<sup>2+</sup> and Mn<sup>2+</sup>). These elements trigger the ICD effect through reactive oxygen species accumulation and stimulate the STING pathway to activate immune cells effectively. Strategic placement of this battery around subcutaneous tumor sites results in a 99.6% growth inhibition rate after a 14-day treatment. This work demonstrates a powerful electrochemical tool for drug-free cancer immunotherapy, which may open an avenue for sustained and localized delivery of immune agonists.
Medical subject headings
- Manganese Compounds
- Tumor Microenvironment
- Immunotherapy
- Zinc
- Oxides
- Neoplasms